Similar trends in serum VEGF-D levels and kidney angiomyolipoma responses with longer duration sirolimus treatment in adults with tuberous sclerosis
| Autor: | David Neal Franz, Jan L. Paolini, Elizabeth A. Thiele, Drew Cutler, Sandra L. Dabora, Vidhya Kumar, Izabela A. Malinowska, Darcy A. Krueger, Nancy Lee, Arthur I. Sagalowsky, Stephen Ashwal, Francis J. DiMario, S. Camposano |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Male
Angiomyolipoma Time Factors Anatomy and Physiology Pulmonology Vascular Endothelial Growth Factor D Cancer Treatment lcsh:Medicine Kidney Cardiovascular Gastroenterology Biochemistry Pulmonary function testing Tuberous sclerosis 0302 clinical medicine Tuberous Sclerosis Chronic Kidney Disease Clinical Trials (Cancer Treatment) lcsh:Science 0303 health sciences Multidisciplinary Clinical Pharmacology Kidney Neoplasms 3. Good health medicine.anatomical_structure Oncology Nephrology 030220 oncology & carcinogenesis Renal Cancer Blood Chemistry Medicine Female medicine.drug Research Article Adult medicine.medical_specialty Drugs and Devices Drug Research and Development Clinical Research Design Urology Context (language use) Cardiovascular Pharmacology 03 medical and health sciences Vascular Biology Internal medicine medicine Humans Clinical Trials Biology 030304 developmental biology Sirolimus Renal Physiology business.industry Kidney Angiomyolipoma lcsh:R Renal System medicine.disease equipment and supplies Endocrinology lcsh:Q business Kidney disease |
| Zdroj: | PLoS ONE PLoS ONE, Vol 8, Iss 2, p e56199 (2013) |
| ISSN: | 1932-6203 |
| Popis: | Context We have previously shown that serum VEGF-D is elevated at baseline, correlates with kidney angiomyolipoma size at baseline and 12 months, and decreases with sirolimus treatment in adults with tuberous sclerosis complex (TSC). To further investigate the utility of serum VEGF-D for longer term monitoring of TSC kidney disease, we present VEGF-D level results with 24 month follow-up. Objective To compare 24 month VEGF-D levels in two subgroups of sirolimus treated patients (OFF SIROLIMUS AFTER 12 MONTHS or ON SIROLIMUS AFTER 12 MONTHS). Design and Intervention(s) Serum VEGF-D was measured in samples collected from subjects enrolled in a phase 2 multicenter trial evaluating sirolimus for the treatment of kidney angiomyolipomas associated with TSC or TSC/LAM. All participants were treated with sirolimus from 0–12 months. During months 12–24, sirolimus was discontinued in one subgroup. The other subgroup was treated with additional sirolimus. Setting Adult TSC participants were recruited from six clinical sites in the United States (comprehensive TSC clinics, 5; urology clinic, 1). Patients There were 28 TSC patients who completed all 24 months of the study and serum samples were available at 24 months from 18/28 patients. Main Outcome Measure(s) We compared the percent change in VEGF-D levels (baseline to 24 months) in patients from the two treatment subgroups. Results At 24 months, VEGF-D levels decreased by 67% compared with baseline (to 787±426 pg/ml) in the ON SIROLIMUS AFTER 12 MONTHS group versus a 13% decrease (to 2971±4014 pg/ml) in the OFF SIROLIMUS AFTER 12 MONTHS group (p = 0.013, Mann-Whitney test). A similar trend was observed in kidney angiomyolipoma size but not in pulmonary function tests. Conclusions Serum VEGF-D may be useful for monitoring response to treatment with sirolimus and kidney angiomyolipoma size in patients with TSC, but confirmation is needed. Trial Registration Clinical trials.gov NCT00126672. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|